Literature DB >> 8054246

In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.

D J Birkett1, D Rees, T Andersson, F J Gonzalez, J O Miners, M E Veronese.   

Abstract

1. The activation of proguanil to cycloguanil by human liver microsomes was studied to define the cytochrome P450 (CYP) isoforms involved in this reaction. 2. Apparent Km values for proguanil ranged from 35 microM to 183 microM with microsomes from four human livers. 3. There was a 6.3-fold range of activity with microsomes from seventeen human livers. Rates of proguanil activation correlated significantly with CYP3A activities (benzo[a]pyrene metabolism, caffeine 8-oxidation and omeprazole sulphone formation) and CYP3A immunoreactive content. There was also a highly significant correlation with rates of hydroxyomeprazole formation. Correlations with activities selective for CYP1A2, CYP2C9/10 and CYP2E1, and with immunoreactive CYP1A2 content were not significant. 4. Proguanil activation was inhibited by R,S-mephenytoin, troleandomycin and by inhibitory anti-CYP3A antiserum and anti-CYP2C IgG and was activated by alpha-naphthoflavone. Inhibitors selective for CYP1A2, CYP2E1, CYP2A6 or CYP2C9/10 had little or no effect on proguanil activation. The extents of inhibition by R,S-mephenytoin, troleandomycin and the two antibodies varied with the immunoreactive CYP3A content of the microsomes used. 5. It is concluded that proguanil activation to cycloguanil by human liver microsomes is mediated both by S-mephenytoin hydroxylase and isoforms of the CYP3A subfamily. This has implications for the use of proguanil as an in vivo probe for the S-mephenytoin poor metaboliser phenotype.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8054246      PMCID: PMC1364895          DOI: 10.1111/j.1365-2125.1994.tb05707.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Mephenytoin-type polymorphism of drug oxidation: purification and characterization of a human liver cytochrome P-450 isozyme catalyzing microsomal mephenytoin hydroxylation.

Authors:  J Gut; U T Meier; T Catin; U A Meyer
Journal:  Biochim Biophys Acta       Date:  1986-12-10

Review 2.  Genetic polymorphism of S-mephenytoin hydroxylation.

Authors:  G R Wilkinson; F P Guengerich; R A Branch
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

3.  Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man.

Authors:  S A Ward; W M Watkins; E Mberu; J E Saunders; D K Koech; H M Gilles; R E Howells; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

4.  Family studies of mephenytoin hydroxylation deficiency.

Authors:  T Inaba; M Jurima; W Kalow
Journal:  Am J Hum Genet       Date:  1986-05       Impact factor: 11.025

5.  S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families.

Authors:  S A Ward; F Goto; K Nakamura; E Jacqz; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1987-07       Impact factor: 6.875

6.  Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man.

Authors:  M D Edstein; J R Veenendaal; H V Scott; K H Rieckmann
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

7.  Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450.

Authors:  M E McManus; W M Burgess; M E Veronese; A Huggett; L C Quattrochi; R H Tukey
Journal:  Cancer Res       Date:  1990-06-01       Impact factor: 12.701

8.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects.

Authors:  Y Wattanagoon; R B Taylor; R R Moody; N A Ochekpe; S Looareesuwan; N J White
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

10.  High-performance liquid chromatographic assay for 4-nitrophenol hydroxylation, a putative cytochrome P-4502E1 activity, in human liver microsomes.

Authors:  W Tassaneeyakul; M E Veronese; D J Birkett; J O Miners
Journal:  J Chromatogr       Date:  1993-06-23
View more
  17 in total

Review 1.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 2.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Genetic polymorphism of CYP2C19 in Maharashtrian population.

Authors:  Yogita Ghodke; Kalpana Joshi; Yashendra Arya; Anjali Radkar; Aditi Chiplunkar; Pooja Shintre; Bhushan Patwardhan
Journal:  Eur J Epidemiol       Date:  2007-11-03       Impact factor: 8.082

4.  Aminoindoles, a novel scaffold with potent activity against Plasmodium falciparum.

Authors:  Robert H Barker; Sameer Urgaonkar; Ralph Mazitschek; Cassandra Celatka; Renato Skerlj; Joseph F Cortese; Erin Tyndall; Hanlan Liu; Mandy Cromwell; Amar Bir Sidhu; Jose E Guerrero-Bravo; Keila N Crespo-Llado; Adelfa E Serrano; Jing-Wen Lin; Chris J Janse; Shahid M Khan; Manoj Duraisingh; Bradley I Coleman; Inigo Angulo-Barturen; María Belén Jiménez-Díaz; Noemí Magán; Vanesa Gomez; Santiago Ferrer; María Santos Martínez; Sergio Wittlin; Petros Papastogiannidis; Thomas O'Shea; Jeffrey D Klinger; Mark Bree; Edward Lee; Mikaela Levine; Roger C Wiegand; Benito Munoz; Dyann F Wirth; Jon Clardy; Ian Bathurst; Edmund Sybertz
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

Review 5.  Drug interactions with proton pump inhibitors.

Authors:  P Unge; T Andersson
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

6.  Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.

Authors:  J K Coller; A A Somogyi; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

Review 7.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

9.  Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population.

Authors:  J M Hoskins; G M Shenfield; A S Gross
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

10.  Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population.

Authors:  R Setiabudy; M Kusaka; K Chiba; I Darmansjah; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.